Recombinant Human Epimorphin/Syntaxin 2 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Epimorphin/Syntaxin 2 Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion and survival of Mv1Lu mink lung epithelial cells. Koshida, S. and Hirai, Y. (1997) Biochem. Biophys. Res. Commun. 234:522.

  The ED₅₀ for this effect is 0.3-1.2 μg/mL.

• Source: E. coli-derived human Epimorphin/Syntaxin 2 protein
  Met1-Arg188
• Accession #: P32856
• N-terminal Sequence: Met1
• Protein/Peptide Type: Recombinant Proteins
• Gene: STX2
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 21.8 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 23 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and DTT.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Epimorphin/Syntaxin 2 Protein, CF

• EPIMepimorphin
• Epimorphin
• EPM
• STX2
• STX2AMGC51014
• STX2Bsyntaxin-2
• STX2CEpimorphin
• Syntaxin 2

Background

Epimorphin (EPIM), also known as syntaxin 2 (STX2), is a type IV transmembrane protein that is a member of the syntaxin family of t‑SNARE (target‑Soluble NSF Attachment REceptor) membrane fusion proteins (1 ‑ 4). Intracellular Epimorphin functions as a vesicle fusion protein, but extracellular forms that are active in morphogenesis are also found. Human Epimorphin cDNA encodes 289 amino acids (aa) including a coiled‑coil domain (aa 35 ‑ 101), a potential cell‑recognition sequence (aa 105 ‑ 123), a sequence important for membrane transduction (aa 141 ‑ 150), a t‑SNARE domain (aa 191 ‑ 252), and a C‑terminal transmembrane domain (aa 265 ‑ 288) (1 ‑ 4). Within aa 1 ‑ 188, human Epimorphin shares 89%, 88%, 94% and 95% aa sequence homology with mouse, rat, bovine and porcine Epimorphin, respectively. Potential isoforms of 287 and 277 aa show C‑terminal substitutions that do and do not contain hydrophobic sequences, respectively (1). Epimorphin has no signal sequence, but cell stress or Ca²⁺ influx induces plasma membrane crossing, with the assistance of annexin A2 and synapatotagmin‑1 (5). A soluble, extracellular 30 kDa form of Epimorphin is produced from the membrane–associated 34 kDa form by cleavage between E245 and H246 (2, 5 ‑ 7). Intracellular 70 kDa and 150 kDa complexes are presumed to be dimers and tetramers, respectively (1, 2, 6). Epimorphin produced by mesenchymal cells influences morphogenesis of epithelia in the breast, kidney, intestine, lung, pancreas, liver, skin and intestines (2, 4, 5). For cells such as lung, mammary or pancreatic epithelia, soluble Epimorphin promotes tubulogenesis or hollow sphere formation in vitro, while epithelia plated on Epimorphin or Epimorphin‑producing cells exhibit alpha v integrin‑dependent adhesion and branching morphogenesis (2 ‑ 8). Mice genetically lacking Epimorphin are sterile due to abnormal spermatogenesis and testicular development (9, 10). Both endogenous and exogenous Epimorphin are shown to protect cells from oxidative stress (11, 12).

1. Hirai, Y. (1993) Biochem. Biophys. Res. Commun. 191:1332.
2. Hirai, Y. et al. (1992) Cell 69:471.
3. Koshida, S. and Y. Hirai (1997) Biochem. Biophys. Res. Commun. 234:522.
4. Chen, C.S. et al. (2009) J. Biol. Chem. 284:6877.
5. Hirai, Y. et al. (2007) J. Cell Sci. 120:2032.
6. Lehnert, L. et al. (2001) J. Cell Biol. 152:911.
7. Hirai, Y. et al. (1998) J. Cell Biol. 140:159.
8. Fritsch, C. et al. (2002) J. Clin. Invest. 110:1629.
9. Akiyama, K. et al. (2008) J. Reprod. Dev. 54:122.
10. Wang, Y. et al. (2006) J. Clin. Invest. 116:1535.
11. Kinoshita, N. et al. (2011) J. Gastroenterol. Hepatol. 26:201.
12. Iizuka, M. et al. (2007) Am. J. Physiol. Gastrointest. Liver Physiol. 292:G39.

Publications for Epimorphin/Syntaxin 2 (2936-EP)(1)

Publication using 2936-EP

• Pritchett J, Athwal V, Harvey E, Martin K, Llewellyn J, Ireland P, Nicolaides A, Humphries M, Bobola N, Hanley N, Piper Hanley K Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells. PLoS ONE, 2014-06-27;9(6):e100091. 2014-06-27 [PMID: 24971829] (Bioassay, Rat)

Bioinformatics

• Gene Symbol: STX2
• Uniprot:
  • P32856()